Literature DB >> 9914793

A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex.

M Hanada1, S Mizuno, A Fukushima, Y Saito, T Noguchi, T Yamaoka.   

Abstract

Amrubicin is a novel, completely synthetic 9-aminoanthracycline derivative. Amrubicin and its C-13 alcohol metabolite, amrubicinol, inhibited purified human DNA topoisomerase II (topo II). Compared with doxorubicin (DXR), amrubicin and amrubicinol induced extensive DNA-protein complex formation and double-strand DNA breaks in CCRF-CEM cells and KU-2 cells. In this study, we found that ICRF-193, a topo II catalytic inhibitor, antagonized both DNA-protein complex formation and double-strand DNA breaks induced by amrubicin and amrubicinol. Coordinately, cell growth inhibition induced by amrubicin and amrubicinol, but not that induced by DXR, was antagonized by ICRF-193. Taken together, these findings indicate that the cell growth-inhibitory effects of amrubicin and amrubicinol are due to DNA-protein complex formation followed by double-strand DNA breaks, which are mediated by topo II.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9914793      PMCID： PMC5921721          DOI： 10.1111/j.1349-7006.1998.tb00519.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


  26 in total

1.  DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.

Authors:  J S Wolverton; M K Danks; B Granzen; W T Beck
Journal:  Cancer Res       Date:  1992-08-01       Impact factor: 12.701

2.  Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events.

Authors:  B S Sørensen; J Sinding; A H Andersen; J Alsner; P B Jensen; O Westergaard
Journal:  J Mol Biol       Date:  1992-12-05       Impact factor: 5.469

3.  Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.

Authors:  K Tanabe; Y Ikegami; R Ishida; T Andoh
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

4.  Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.

Authors:  M J Kuffel; J M Reid; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 5.  Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity.

Authors:  H G Keizer; H M Pinedo; G J Schuurhuis; H Joenje
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

6.  Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity.

Authors:  G Capranico; F Zunino; K W Kohn; Y Pommier
Journal:  Biochemistry       Date:  1990-01-16       Impact factor: 3.162

7.  Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.

Authors:  P B Jensen; B S Sørensen; E J Demant; M Sehested; P S Jensen; L Vindeløv; H H Hansen
Journal:  Cancer Res       Date:  1990-06-01       Impact factor: 12.701

8.  Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.

Authors:  R Ishida; T Miki; T Narita; R Yui; M Sato; K R Utsumi; K Tanabe; T Andoh
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

9.  Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.

Authors:  P B Jensen; P S Jensen; E J Demant; E Friche; B S Sørensen; M Sehested; K Wassermann; L Vindeløv; O Westergaard; H H Hansen
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

10.  Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells.

Authors:  K Bojanowski; S Lelievre; J Markovits; J Couprie; A Jacquemin-Sablon; A K Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205
View more
  35 in total

1.  Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.

Authors:  Satoshi Igawa; Sakiko Otani; Shinichiro Ryuge; Tomoya Fukui; Yoshiro Nakahara; Yasuhiro Hiyoshi; Mikiko Ishihara; Seiichiro Kusuhara; Shinya Harada; Hisashi Mitsufuji; Masaru Kubota; Jiichiro Sasaki; Noriyuki Masuda
Journal:  Invest New Drugs       Date:  2017-06-20       Impact factor: 3.850

2.  Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases.

Authors:  Tomonobu Koizumi; Toshihiko Agatsuma; Takashi Ichiyama; Toshiki Yokoyama; Atsuhito Ushiki; Yoshimichi Komatsu; Tsuyoshi Tanabe; Takashi Kobayashi; Sumiko Yoshikawa; Masanori Yasuo; Hiroshi Yamamoto; Keishi Kubo; Tsutomu Hachiya
Journal:  Med Oncol       Date:  2009-05-05       Impact factor: 3.064

Review 3.  Chemotherapy advances in small-cell lung cancer.

Authors:  Bryan A Chan; Jermaine I G Coward
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

4.  Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer.

Authors:  Takahiko Sugiura; Yutaka Ariyoshi; Shunichi Negoro; Shinichiro Nakamura; Harumichi Ikegami; Minoru Takada; Takashi Yana; Masahiro Fukuoka
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

5.  Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial.

Authors:  Toshiyuki Sawa; Takashi Yana; Minoru Takada; Takahiko Sugiura; Shinzoh Kudoh; Tadashi Kamei; Takeshi Isobe; Hidehiko Yamamoto; Soichiro Yokota; Nobuyuki Katakami; Yuji Tohda; Akira Kawakami; Yoichi Nakanishi; Yutaka Ariyoshi
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

Review 6.  Relapsed small cell lung cancer: treatment options and latest developments.

Authors:  Nobuhiro Asai; Yoshihiro Ohkuni; Norihiro Kaneko; Etsuro Yamaguchi; Akihito Kubo
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

7.  A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901.

Authors:  Toshiyuki Harada; Satoshi Oizumi; Kenichiro Ito; Kei Takamura; Eiki Kikuchi; Tomoya Kuda; Shunichi Sugawara; Aya Suzuki; Makoto Maemondo; Yuka Fujita; Ichiro Kinoshita; Akira Inoue; Fumihiro Hommura; Yutaka Katsuura; Hirotoshi Dosaka-Akita; Hiroshi Isobe; Masaharu Nishimura
Journal:  Oncologist       Date:  2013-02-26

8.  Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treated with platinum-based chemotherapy.

Authors:  Satoshi Oizumi; Koichi Yamazaki; Hiroshi Yokouchi; Jun Konishi; Fumihiro Hommura; Tetsuya Kojima; Hiroshi Isobe; Masaharu Nishimura
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

9.  Effective monotherapy with amrubicin for a refractory extrapulmonary small-cell carcinoma of the liver.

Authors:  Taichi Isobe; Shunichi Yanai; Hitoshi Kusaba; Shinichiro Yada; Yosuke Kuroda; Sadafumi Tamiya; Takayuki Matsumoto; Eishi Baba; Mine Harada
Journal:  Case Rep Med       Date:  2009-06-16

10.  Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin.

Authors:  Michiko Yamamoto; Akira Takakura; Noriyuki Masuda
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.